•
in mil. unless spec.•
in mil. unless spec.•
in mil. unless spec.•
in mil. unless spec.•
in mil. unless spec.•
in mil. unless spec.PAVmed Inc. (PAVM) Q3 2026 Earnings Call Transcript
PAVmed Provides Business Update and Reports Preliminary Third Quarter 2026 Financial Results
Lucid Diagnostics Provides Business Update and Reports Third Quarter 2026 Financial Results
Lucid Diagnostics Recognized as a GenomeWeb Best Place to Work for Second Consecutive Year
Lucid Diagnostics to Participate in the Canaccord Genuity MedTech, Diagnostics and Digital Health & Services Forum
Lucid Diagnostics Announces Publication of Landmark 12,000-Patient Real-World EsoGuard® Study
PAVmed to Hold Third Quarter 2026 Business Update Conference Call and Webcast on November 13, 2026
Lucid Diagnostics to Hold Third Quarter 2026 Business Update Conference Call and Webcast on November 12, 2026
Lucid Diagnostics Begins Receiving Medicare Reimbursement for EsoGuard® and Closes $15 Million Financing
Contrasting PAVmed (NASDAQ:PAVM) and InMode (NASDAQ:INMD)
Lucid Diagnostics Advances Multiple EsoGuard® and EsoCheck® Payment, Billing and Coding Pathways
PAVmed Inc. (PAVM) Q2 2026 Earnings Call Transcript
PAVmed Provides Business Update and Reports Second Quarter 2026 Financial Results
Lucid Diagnostics Provides Business Update and Reports Second Quarter 2026 Financial Results
PAVmed (NASDAQ:PAVM) versus Alpha Tau Medical (NASDAQ:DRTS) Critical Contrast
Lucid Diagnostics Secures Commercial Coverage Policy Spanning Multiple Health Plans for its EsoGuard® Esophageal DNA Test
Lucid Diagnostics to Participate in Upcoming Investor Conferences
PAVmed to Hold Second Quarter 2026 Business Update Conference Call and Webcast on August 14, 2026
Lucid Diagnostics to Hold Second Quarter 2026 Business Update Conference Call and Webcast on August 13, 2026
PAVmed Inc. (PAVM) Shareholder/Analyst Call Prepared Remarks Transcript